AQR Capital Management LLC Sells 34,700 Shares of Tabula Rasa HealthCare Inc (NASDAQ:TRHC)

AQR Capital Management LLC lessened its stake in shares of Tabula Rasa HealthCare Inc (NASDAQ:TRHC) by 88.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,691 shares of the company’s stock after selling 34,700 shares during the period. AQR Capital Management LLC’s holdings in Tabula Rasa HealthCare were worth $234,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Aperio Group LLC bought a new stake in shares of Tabula Rasa HealthCare during the second quarter valued at approximately $39,000. First Mercantile Trust Co. raised its stake in shares of Tabula Rasa HealthCare by 20.3% during the second quarter. First Mercantile Trust Co. now owns 1,197 shares of the company’s stock valued at $60,000 after acquiring an additional 202 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Tabula Rasa HealthCare during the second quarter valued at approximately $82,000. Bank of Montreal Can raised its stake in shares of Tabula Rasa HealthCare by 167.7% during the second quarter. Bank of Montreal Can now owns 2,605 shares of the company’s stock valued at $129,000 after acquiring an additional 1,632 shares in the last quarter. Finally, Neuburgh Advisers LLC raised its stake in shares of Tabula Rasa HealthCare by 18.2% during the second quarter. Neuburgh Advisers LLC now owns 2,704 shares of the company’s stock valued at $135,000 after acquiring an additional 416 shares in the last quarter. 98.75% of the stock is owned by hedge funds and other institutional investors.

TRHC has been the subject of several research analyst reports. BidaskClub downgraded shares of Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research note on Friday. Stifel Nicolaus raised shares of Tabula Rasa HealthCare from a “hold” rating to a “buy” rating and lifted their price target for the company from $50.00 to $75.00 in a research note on Friday, August 30th. ValuEngine raised shares of Tabula Rasa HealthCare from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, September 4th. Finally, Zacks Investment Research downgraded shares of Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research note on Thursday. Three research analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $78.26.

Shares of NASDAQ:TRHC opened at $51.38 on Friday. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of 151.12 and a beta of 1.66. Tabula Rasa HealthCare Inc has a 52 week low of $40.86 and a 52 week high of $83.37. The company has a quick ratio of 1.90, a current ratio of 1.97 and a debt-to-equity ratio of 1.31. The firm has a 50 day moving average of $56.29 and a 200 day moving average of $53.54.

Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.29. The company had revenue of $76.26 million during the quarter, compared to the consensus estimate of $70.40 million. Tabula Rasa HealthCare had a negative net margin of 7.09% and a positive return on equity of 3.63%. Tabula Rasa HealthCare’s revenue for the quarter was up 56.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.20 earnings per share. On average, sell-side analysts expect that Tabula Rasa HealthCare Inc will post -0.15 EPS for the current year.

In related news, Director Gordon Tunstall sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $65.01, for a total value of $650,100.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Calvin H. Knowlton sold 8,000 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $64.13, for a total transaction of $513,040.00. The disclosure for this sale can be found here. Insiders sold 78,000 shares of company stock valued at $4,534,610 in the last three months. 11.80% of the stock is currently owned by insiders.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Further Reading: What is the Fibonacci sequence?

Institutional Ownership by Quarter for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.